XOMAO News and Press, XOMA Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock From 06/23/23

EMERYVILLE, Calif., June 23, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced it has been added to the Russell 2000 ® and Russell 3000 ® Indexes following its annual reconstitution, which took effect after the U.S. markets close...

EMERYVILLE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the royalty and milestone rights associated with two assets from LadRx Corporation: arimoclomol, an oral therapeutic for Niemann-Pick disease type C, and aldoxorubicin, an albumi...

First quarter with incoming cashflows from two commercial assets Completed first royalty asset acquisition under new leadership EMERYVILLE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its first quarter 2023 fin...

2023-03-21 07:47:30 ET XOMA Corp - 8.375% DP PFD B ( NASDAQ: XOMAO ) declares $0.5234/share quarterly dividend , in line with previous. Forward yield 8.82% Payable April 17; for shareholders of record April 4; ex-div April 3. See XOMAO Dividend Scorecard, Yie...

2022 was the first year with cash receipts from a commercial asset since becoming a royalty aggregator Ebopiprant royalty and milestone license acquisition gives XOMA the potential to earn up to $378 million, net, in milestones plus mid-single digit to low teens royalties, net, from Org...

Received first recurring royalty-style payment from Roche related to faricimab, its newly launched therapy for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).  First five months of sales in the U.S. and initial sales in Japan resulted in a $0.5 million c...

XOMA Corporation 8.375% DP PFD B ( NASDAQ: XOMAO ) declares $0.5234/share quarterly dividend , in line with previous. Forward yield 8.42% Payable Oct. 17; for shareholders of record Oct. 3; ex-div Sept. 30. See XOMAO Dividend Scorecard, Yield Chart, & Div...

These July sample selections are the current top positive/negative forensic stocks out of 8,000 stocks based on combined scores from four top forensic algorithms. The January Positive Forensic portfolio is beating the S&P 500 by +1.59% YTD. The Negative portfolio is beating by +13...

While XOMA offers an investment into an important sector of healthcare, drug revenue royalties, the story is just beginning. From first glance, years of losses and flat revenues look poor, but something special is hidden underneath. Those looking to get in before the story plays o...

Earned a $2 million milestone from Rezolute as it dosed the final patient in a Phase 2 open-label study of RZ358 in patients with congenital hyperinsulinism in early 2022.  Rezolute has announced its intention to move RZ358 into Phase 3 clinical development. Roche’s ...